. 2024 Mar 1;35(3):212–222. doi: 10.5152/tjg.2024.23071
Content of this journal is licensed under a Table 2.
Tumor Response in the Total Cohort and Subgroups
|
|
Total | P | BCLC B | P | BCLC C | P | |||
|---|---|---|---|---|---|---|---|---|---|
| TACE-L (n = 51) |
TACE (n = 51) | TACE-L (n = 15) |
TACE (n = 16) | TACE-L (n = 36) |
TACE (n = 35) | ||||
| CR | 2 (3.9%) | 3 (5.9%) | 3 | 1 (6.7%) | 3 (18.75%) | 3 | 1 (2.8%) | 0 (0%) | 3 |
| PR | 15 (29.4%) | 10 (19.6%) | 3 | 6 (40%) | 0 (0%) | 3 | 9 (25%) | 10 (28.6%) | 3 |
| SD | 18 (35.3%) | 12 (23.5%) | 3 | 6 (40%) | 7 (43.75%) | 3 | 12 (33.3%) | 5 (14.3%) | 3 |
| PD | 16 (31.4%) | 26 (51%) | 3 | 2 (13.3%) | 6 (37.5%) | 3 | 14 (38.9%) | 20 (57.1%) | 3 |
| ORR | 33.33% | 25.50% | .128 | 47% | 18.75% | .161 | 28% | 28.57% | .941 |
| DCR | 68.63% | 49.10% | .044 | 86.70% | 62.50% | .124 | 61.1% | 42.90% | .124 |
Data are presented as n (%).
CR, complete response; DCR, disease control rate; L, Lenvatinib; ORR, objective response rate; PD, progressive disease; PR partial response; SD, stable disease; TACE, transarterial chemoembolization.